The session will provide participants with recent clinical trial data on therapeutics for the treatment of ADHD. In addition the symposium will focus on recognizing, reducing, and addressing stimulant abuse and diversion.

This activity is supported by an educational grant from Eli Lilly and Company.

This activity is sponsored by CME LLC. Veritas Institute for Medical Education, Inc. is the content provider.

While Substance Use Disorders have been primarily thought of as those involving chemical substances like tobacco or alcohol , more recently process addictions have been studied . Once the DSM 3 diagnostic scheme was changed to accommodate cocaine and minimize withdrawal or abstinence, gambling and sexual compulsivity have been studied and suggested to be addictions. These process addictions have much neurobiology and phenomenology in common with chemical addictions and this construct may be especially helpful in understanding the obesity epidemic and logical public health and treatment approaches.

Upon the completion of this activity, participants will be able to:

1. Review current epidemiological data on substance abuse disorders.
2. Review examples of common co-occurring disorders such as tobacco smoking and alcohol and depression.
3. List and Discuss diagnostic and treatment issues for co-occurring alcohol and tobacco-related illnesses.

Upon completion of this activity, participants will be able to:

1. Understand how the menstrual cycle and perimenopause can affect psychiatric symptoms;
2. Understand how to modify psychopharmacologic treatment for premenstrual and perimenopausal symptoms;
3. Consider other clinical interventions for premenstrual and perimenopausal psychiatric symptoms

Bipolar disorder presents significant challanges to patients and their mental health and medical treatment team. Accurate diagnosis is essential to prevent making the situation worse. Treatment is complicated with ever changing treatment needs and goals.

By participating in this session, learners will be able to:

1. More accurately diagnose and successfully manage BD;
2. Utilize current advances in the use of combination versus monotherapy to optimize relapse prevention in the acute and long-term management of BD;
3. Identify strategies to optimize individual patient management of BD including related psychiatric and medical comorbidities and improve adherance rates;
4. Understand the role of antidepressants in the treatment of BD.

The session will provide participants with strategies for the management of adolescents with depression.

This activity is supported by an educational grant from Forest Laboratories, Inc.

This activity is jointly sponsored by The Albert Einstein College of Medicine with Montefiore Medical Center and CME LLC.  The Institute for Continuing Healthcare Education is the content provider.

The session will provide participants with practical strategies for the diagnosis, treatment, and long term management of patients with schizophrenia.

12:15 - 12:45 p.m. Lunch
12:45- 2:15 p.m. Symposium

This activity is supported by an educational grant from Eli Lilly and Company.
This activity is sponsored by CME LLC. CME Outfitters is the content provider.

Upon the completion of this activity, participants will be able to:

1. Understand how pregnancy and the postpartum period affect the course and expression of mood disorders;
2. Understand the risks of untreated symptoms of mood disorders during pregnancy and postpartum;
3. Understand the risks of antidepressant and mood-stabilizing medications during pregnancy and postpartum, and prescribing practices that can minimize risks

Fibromyalgia syndrome affects 3-5% of the population and is the second most common presenting complaint in rheumatology. Primary care providers have difficulty caring for patients with fibromyalgia due to a wide array of pain and non-pain complaints including headache, abdominal pain, irritable bladder, jaw pain, insomnia, numbness and difficulty concentrating as well as others. Many of the presenting complaints may be psychologic in nature, but the underlying disease is distinct from the presenting depressive and anxiety symptoms. Sorting the myriad complaints and providing structure can be lifesaving for patients with fibromyalgia and is best treated by those skilled in psychology.

At the end of this activity, attendees will be able to:

1. Describe the current science about the pathophysiology of fibromyalgia syndrome;
2. Help the referring provider to manage the pain and psychosocial issues; and
3. Treat patients with pharmacologic and nonpharmacologic options.

The session will provide participants with insight into insomnia management through discussions of assessment, treatment implications, and patient education strategies.

7:00-7:30 a.m. Breakfast
7:30-9:00 a.m. Symposium

This activity is supported by an educational grant from sanofi-aventis U.S.
This activity is sponsored by CME LLC. MediCom Worldwide, Inc. is the content provider.

Treating patients who suffer from Anorexia and/or Bulimia can cause psychiatrists and psychotherapists tremendous frustration or great satisfaction. Successful treatment of Eating Disorders requires a complete understanding of the multiple etiologies involved, the psychotherapies required and the sophisticated use of psychotropic medications. We will focus in this session on the keys optimizing clinical outcomes and achieving remission based upon the biopsychosocial etiology of these disorders. We will identify the factors that result in failure and frustration, as well as the keys to successfully reach appropriate treatment goals.

By participating in this activity, learners will be able to:

1. Understand the multimodal treatment necessary for the successful treatment of these biopsychosocial disorders.
2. Enhance their ability to successfully utilize cognitive/behavioral psychotherapeutic techniques within a dynamic understanding of Anorexia and Bulimia.
3. Update their ability to successfully utilize psychopharmacologic agents to treat Eating Disorders.

While we attempt to make evidence-based decisions, the evidence in Psychiatry is incomplete and contradictory. Psychiatry is usually practiced behind closed doors in 1 to 1 confidential patient interactions. We want to learn how our psychiatric colleagues make difficult psychiatric decisions and treatment recommendations, but we have few opportunities to do so. Do they prescribe antidepressants for bipolar depression? or give benzodiazepines to patients with histories of substance abuse? How do they choose between augmentation options? Etc. When, Why and How do they make these and other complex treatment decisions? Join us in this stimulating interactive session as we utilize computerized response systems to explore these treatment questions and dilemmas. Learn, engage and participate with us. Bring your own cases, questions and treatment dilemmas.

By participating in this session, learners will be able to:

1. Learn how fellow psychiatric colleagues approach challenging treatment decisions in Mood and Anxiety Disorders.
2. Recognize the need for treatment decisions to be based on scientific evidence and clinical experience and acumen.
3. Enhance your ability to successfully treat Mood and Anxiety Disorders.

Health care reform has opened the door to integrating psychiatric mental health and behavioral interventions into medical settings. With a call for the Integrated Medical Home, prevention and patient wellness education will be rewarded as an innovation that will drive down medical costs. This opens the door for psychiatric mental health practitioners of all levels to apply the evidence based practices of the field to short term treatments in primary care settings. To capitalize on this evolution of our professions, we need to understand how to work collaboratively with medical offices, and the new NCQA standards for the patient centered medical home that focuses on early identification, patient education and modalities that can be effective in treatment of psychiatric mental health and behavioral issues in the primary care environment. By understanding the business issues involved with using commercial-based insurance, psychiatric nurses (RN,CNS, or NP), and other psychiatric mental health clinicians will have new opportunities to engage his or her full scope of practice that will directly impact patients' lives.

Participants should be able to:

1. Identify elements of collaboration in medical setting;
2. Understand what is needed to get credentialed and paid for collaborative services;
3. Define the role and training needs to participate in collaborative care;
4. Illuminate the issues involved in creating a model of collaborative care programs in your community; and
5. Understand the steps needed in developing community outreach and collaboration tools.

The session will provide participants with practical tools for the continuity of care for patients with schizophrenia.

This activity is supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC

This activity is jointly sponsored by the Indiana University School of Medicine and CME LLC. CME Outfitters is the content provider.

The session will provide participants strategies and reinforcement in dose titration, multimodal treatment, and long-term treatment adherence for patients with ADHD.

12:15 - 12:45 p.m. Lunch
12:45- 2:15 p.m. Symposium

This activity is supported by an educational grant from McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC

This activity is jointly sponsored by The Albert Einstein College of Medicine with Montefiore Medical Center and CME LLC. Veritas Institute for Medical Education Inc. is the content provider.

The session will provide participants with strategies for improving the management of comorbid depression as well as chronic pain and other physical symptoms.

12:15PM-12:45 p.m. Lunch
12:45-2:15 p.m. Symposium

This activity is supported by an educational grant from Eli Lilly and Company.

This activity is jointly sponsored by The Albert Einstein College of Medicine with Montefiore Medical Center and CME LLC. The Institute for Continuing Healthcare Education is the content provider.

Walking away from the closed door of our office, into medical offices, opens the door for new applications of psychiatric mental health and behavioral interventions that will drive down medical costs. Collaborating with primary care providers directly in medical offices requires new skills built on the understanding of the office, community and patient cultures. This discussion about the integrated mental health will focus on clinical issues, skill development, complementary and alternative mental health practices and how to work with health care reform to perpetuate a new clinical environment rich in opportunities for clinical research and outcome studies. This presentation will address behavioral interventions indicated for several medical conditions (diabetes, cardiac disease, infertility, pulmonary disease, and autoimmune diseases) as well as the collaborative process. While this presentation will highlight the role of psychiatric nurse in this exciting milieu, it could enhance the knowledge base of all practitioners interested in participating in a integrated medical home.

Participants should be able to:

1. Identify boundaries to the collaborative process and appropriate safeguards for patient information;
2. Define the process for comprehensive assessment and wellness planning;
3. Define the impact of mental illness on specific diseases discussed;
4. Identify collaborative involvement, role in referral and follow up;
5. Develop a tool specific to attendees' practices that will enhance the role, health care management, and communication between team members.

The evidence base for pharmacotherapy of PTSD has grown by leaps and bounds in the past 10 years. Early studies of amitriptyline and phenelzine showed some promise for treatment of PTSD. But sample sizes were small and larger-scale studies have not been conducted. Only one class of drugs, the selective serotonin reuptake inhibitor (SSRIs) has members of the class FDA-approved for PTSD. Numerous large, multi-center trials of SSRIs (and, more recently, several large trials with dual norepinephrine serotonin reuptake inhibitors [NSRIs]) conclusively demonstrate their short- and intermediate-term efficacy, but response rates are modest and the optimal duration of treatment is unclear. Furthermore, the efficacy of SSRIs in some populations (e.g., combat veterans with PTSD) has been questioned. As awareness of the prevalence and seriousness of PTSD has increased, so has the impetus to develop new and better treatments. Several other classes of medications, including anticonvulsants, atypical antipsychotics, and adrenergic agents (e.g., prazosin) have shown promise in relatively small studies for either monotherapy or adjunctive use. For some medications, large randomized controlled trials (RCTs) have been negative (e.g., the anticonvulsant tiagabine), whereas for others such trials are either ongoing (e.g., prazosin and risperidone) or have yet to be conducted (e.g., lamotrigine). A role for combined psychotherapy and pharmacotherapy of PTSD will be discussed.

Upon the completion of this activity, particpants will be able to:

1. List FDA approved treatments for posttraumatic stress disorder (PTSD).
2. Identify the different classes of psychotropic agents that may be useful in the treatment of PTSD.
3. Discuss the limitations of the available evidence base for PTSD pharmacotherapy and of the need for more studies and better therapeutics.

The session will provide participants with education on the proper screening, diagnosis, and treatment of ADHD in children, adolescents, and adults.

7:00-7:30 a.m. Breakfast
7:30-9:00 a.m. Symposium

This educational activity is supported by an independent medical educational grant from Shire.
This activity is sponsored by CME LLC. Veritas Institute for Medical Education, Inc. is the content provider.

The session will provide participants with strategies for improving rates of remission for major depressive disorder (MDD), including treatment resistant depression, along with combination and augmentation strategies for depression with atypical antipsychotics.

This activity is supported by an educational grant from Bristol-Myers Squibb and Otsuka America Pharmaceutical, Inc.

This activity is jointly sponsored by The Albert Einstein College of Medicine with Montefiore Medical Center and CME LLC. The Institute for Continuing Healthcare Education is the content provider.

Medication adherence can be a major challenge in patient care. This course will cover ten specific, practical and easily adopted interviewing techniques to improve medication adherence. These techniques are derived from the highly acclaimed motivational strategy known as the "medication interest model."

By participating in this activity, attendees will be able to:

1. Apply techniques such as the "inquiry into lost dreams" and the "trap-door question";
2. Identify the challenges in medication adherence by understanding how and why patients weigh the pros and cons of taking medications; and
3. Demonstrate the principles and applications of the medication interest model in a sophisticated fashion to a variety of difficult clinical situations.

Headache is one of the most common of human afflictions. Nearly 30 million Americans live with migraine, but only a fraction of them receive effective treatment. The impact of inadequate or ineffective care is enormous, in both direct and indirect costs. The course discusses the update in the diagnosis and management of both primary and secondary headache disorders.

By participating in this activity, attendees will be able to:

1. Differentiate primary headache disorder from headache symptomatic of other disease;
2. Identify both episodic and chronic primary headache disorders; and
3. Discuss the treatment plans for both primary and secondary headache disorders.

Upon the comletion of this activity, participants will be able to:

1. Define depression;
2. Outline causes and features of late life depression and discuss the known treatment modalities;
3. Assess therapy outcomes and how to improve these and;
4. Describe the need for maintenance therapy.

In 1984, Libby Zion died of a fatal drug interaction, and her death led to our present system of residency workplace hourly restrictions. Despite these changes, would a well-rested clinician be able to recognize and prevent her death today?

By participating in this activity, attendees will be able to:

1. Recognize clinically relevant drug interactions;
2. Utilize a framework and teaching tool to predict those patients most at risk for serotonin syndrome and other drug interactions; and
3. Describe the cytochrome P450 system.

Upon the completion of this activity, participants will be able to:

1. List Five Strategies to Modify Delivery of Medications;
2. Explain what are the possible pharmacodynamic advantages, which result from dosage formulation related changes in drug concentrations at their sites of action;
3. Identify future strategies for drug delivery and monitoring systems;
4. Summarize data available supporting (or not) the advantages of novel dosage forms;
5. Describe research strategies (and clinical approaches) to study the safety and efficacy of novel antipsychotic dosage forms.

This talk explores the ongoing concerns about the increase in the popularity of a socially designated class of drugs known as "club drugs."

By participating in this activity, attendees will be able to:

1. Discuss the major categorization of club drugs and their pharmacological properties;
2. Identify the clinical and psychiatric manifestations of club drugs; and
3. Recognize available treatment approaches and harm reduction and prevention strategies.

This Lecture will outline the current thinking about Tourette syndrome since it often includes co-morbid ADHD, OCD, and Anxiety Disorders. The make up of this trinity will be discussed and the ramification of making this diagnosis, as well as impart on insurability, and the natural cause of the disorder. Medication use for symptoms in the context of the comorbid problems will be discussed.

By participating in this education activity, participants will be able to:

1. List the symptoms of Tourette's syndrome and differentiate the types of tics and movements which are often associated with this syndrome.
2. Recognize the potentiality for co-morbid diagnoses like ADHD and OCD.
3. Discuss the characteristics of a proper evaluation and also appreciate what not to do.
4. List resources to help patients and families once a diagnosis is made.
5. Understand the role of medications in treating the tics as well as the co-morbidities.

Upon the completion of this activity, participants will be able to:

1. Describe the relative risk of comorbid substance abuse with other psychiatric syndromes.
2. Identify the available pharmacological agents for treatment of dual-diagnosis patients and medication treatment for substance dependence disorders.
3. Discuss the difficulties relating to the treatment and the harm reduction model vs. the abstinence model for dual-diagnosis patients.